MaxCyte (US:MXCT) — Company Overview, News & Financial Data
MaxCyte specializes in cell engineering tools to support the development of cell therapies and biotherapeutics globally.
MaxCyte
MaxCyte (NASDAQ:MXCT) specializes in cell engineering, providing essential tools and technologies that support the development and commercialization of cellular therapies and biotherapeutics. The company's cutting-edge Flow Electroporation technology and instruments facilitate the discovery, development, and manufacture of new therapies, particularly in the field of immune-oncology, cell therapy, and gene editing. MaxCyte aims to accelerate the fight against a wide range of diseases, including cancer, inherited diseases, and infectious diseases, by empowering researchers and pharmaceutical companies to unlock the full potential of their cell-based research. Serving a global clientele, MaxCyte is committed to innovation and excellence in supporting the advancement of science and medicine.
Snapshot
Operations
Products and/or services of MaxCyte
- Flow Electroporation Technology - A platform facilitating high-performance cell engineering for research, bioprocessing, and therapeutic applications.
- ExPERT instrument family - Includes ATx, STx, and GTx models tailored for advanced gene editing, cell therapy development, and protein expression optimization.
- CARMA Platform - Utilizing mRNA-based cell therapies for developing treatments against solid tumors and other diseases through a proprietary cell therapy platform.
- Life Sciences Research Instruments - Offering high-quality instruments and tools for cellular engineering, including electroporation buffers and accessories.
- Clinical and Commercial Licensing - Provides partners with access to its technology for development of cell-based therapies, including several partnerships with leading pharmaceutical companies.
- Cell Engineering Services - Custom service offerings to support the development and optimization of cell-based therapies, including process development and training.
MaxCyte executive team
- Mr. Maher MasoudPresident, CEO & Executive Director
- Mr. Douglas J. Swirsky CFA, CPAChief Financial Officer
- Mr. Jay GelfmanSenior Vice President of Operations
- Mr. Jack HorganSenior Vice President of Corporate Development
- Ms. Ana-Paula Martins FernandesSenior Vice President of Global Sales
- Ms. Jill MayerSenior Vice President of Human Resources